Medicine Questions

Report an Adverse Event

Investors

Contact

Global Operations

North America

Canada
Mexico
USA

South America

Argentina
Brazil

Asia

China Mainland
Hong Kong
India
Japan
Korea
Singapore
Taiwan

Middle East

Israel
Saudi Arabia
Türkiye
United Arab Emirates

Africa

South Africa

Australia

Australia and New Zealand

Europe

Austria
Belgium and Luxembourg
Czech Republic & Slovakia
Denmark
Finland
France
Germany
Greece
Iceland
Ireland

Italy
Netherlands
Norway
Poland & The Baltics
Portugal
Romania
Russia
Spain
Sweden
Switzerland
United Kingdom

Our Company
Mission and Core Values Leadership Public Policy Engagement Policies and Disclosures Supplier Information U.S. Locations
Our Purpose
Partnerships and Community Corporate Giving Gilead Foundation Inclusion and Diversity Environmental, Social, Governance (ESG) Sustainability Advancing Global Health Medication Access
Science & Medicine
Therapeutic Areas Medicines Pipeline Research Clinical Trials
News and Press
Events Stories Newsroom Company Statements Annual Reports
Careers
Careers at Gilead Our Culture Meet Our Employees Inclusion and Diversity in Hiring Compensation, Benefits and Wellbeing Our Global Footprint Early Career Opportunities Postdoctoral Fellowships Hiring Events Talent Community Sign-up
Utility
Privacy Statements Terms Of Use Social Media Guidelines Sitemap

BACK TO MAIN MENU Leadership Governance and Committees

BACK TO MAIN MENU Public Policy Engagement Political Contributions Archives

BACK TO MAIN MENU Policies and Disclosures Policies Disclosures

BACK TO MAIN MENU Supplier Information COVID-19 Vaccination Guidance for Suppliers Supplier Enablement Resources Supplier Inclusion

BACK TO MAIN MENU Partnerships and Community COMPASS Initiative HepConnect HIV Age Positively Toward Health Equity for Black People Impacted by TNBC RADIAN TRANScend

BACK TO MAIN MENU Corporate Giving What We Fund Funding Requests Zeroing In: Ending the HIV Epidemic

BACK TO MAIN MENU Gilead Foundation Creating Possible Fund

BACK TO MAIN MENU Environmental, Social, Governance (ESG) Reporting U.N. Global Compact U.N. Sustainable Development Goals

BACK TO MAIN MENU Sustainability Our Business Is Sustainable Performance

BACK TO MAIN MENU Advancing Global Health COVID-19 HCV Elimination

BACK TO MAIN MENU Medication Access U.S. Patient Access Disaster Product Replacement Global Access Authorized Distributors

BACK TO MAIN MENU Research Research Scholars Program Compassionate Use Investigator-Sponsored Research

BACK TO MAIN MENU Newsroom Press Releases Media Inquiries

BACK TO MAIN MENU Company Statements Christi Shaw to Depart Gilead and Kite Leadership End of Q1 Gilead Sciences Commends Convictions in Counterfeiting Scheme Pledges Continued Commitment to Protect Patients Gilead Enables Easier Veklury® (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Gilead to Expand Footprint in Oceanside Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines

BACK TO MAIN MENU Annual Reports Year in Review 2021

BACK TO MAIN MENU Early Career Opportunities Internship Program

BACK TO MAIN MENU Privacy Statements Cookie Statement Global Applicant Privacy Statement

BACK TO MAIN MENU

North America

Canada
Mexico
USA

South America

Argentina
Brazil

Asia

China Mainland
Hong Kong
India
Japan
Korea
Singapore
Taiwan

Middle East

Israel
Saudi Arabia
Türkiye
United Arab Emirates

Africa

South Africa

Australia

Australia and New Zealand

Europe

Austria
Belgium and Luxembourg
Czech Republic & Slovakia
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Netherlands
Norway
Poland & The Baltics
Portugal
Romania
Russia
Spain
Sweden
Switzerland
United Kingdom

BACK TO MAIN MENU

Contact

Request Medicines Information
Report an Adverse Event
Partnership Request

Search Term

Medicine Questions
Report an Adverse Event
Investors
Contact
Global Operations

Toggle Inner Dropdown

BACK TO MAIN MENU Google.com

Mission and Core Values
Leadership
- Governance and Committees
Public Policy Engagement
- Political Contributions Archives
Policies and Disclosures
- Policies
- Disclosures
Supplier Information
U.S. Locations

Vermont Disclosures

© 1996-2023 Gilead Sciences, Inc. All rights reserved.

AREAS OF INTEREST

Careers
Environmental, Social, Governance (ESG)
Medicines
Partnerships and Community
Pipeline
Stories@Gilead

INFORMATION

Contact Us
Investor Calls
Press Room
Report an Adverse Event
Sitemap

LEGAL

Cookie Statement
Modern Slavery Act Statement
Privacy Statement
Public Policy Engagement
Social Media Guidelines
Terms of Use

FOLLOW US

Headline

Intersititial body copy

Ok Cancel